北大医药：子公司北医医药6月以来主营业务已基本中止

Core Viewpoint - The company, Peking University Pharmaceutical (000788), announced the termination of its long-term service contract with Peking University International Hospital, which is expected to significantly impact its business operations and financial performance after May 2025 [1] Business Operations - The company's wholly-owned subsidiary, Beijing Peking University Medicine Co., Ltd. (referred to as "Peking Medicine"), has heavily relied on its business cooperation with the International Hospital, and this partnership will end in May 2025 [1] - Following the termination, Peking Medicine's main business is expected to cease, leading to a transition phase for the business [1] Financial Impact - The company anticipates a potential revenue decrease of approximately 600 million yuan (about 29.13% of the most recent audited revenue) from June 2025 to the end of 2025 [1] - The expected net profit reduction is around 40 million yuan (approximately 28.99% of the most recent audited net profit attributable to the parent company) during the same period [1] - From 2026 onwards, the company may face a revenue decline of about 1.027 billion yuan (approximately 49.85% of the most recent audited revenue) and a net profit decrease of around 68.69 million yuan (about 49.78% of the most recent audited net profit attributable to the parent company) [1]